Dose counter mechanism for mometasone furoate dry powder inhaler "has not been proven to be accurate or reliable," Jan. 19 FDA 483 inspection report states. Manual counts did not match the numbers displayed by the inhaler device's counter, FDA observed. The counting mechanism also exhibited "jamming" and would not decrement as intended. The once-daily corticosteroid has been "approvable" since October 1999 for treatment of asthma in patients 12 and older. The 483 was released by Public Citizen March 1 (1see related story, p. 6)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The European Medicines Agency has revised the sponsor handbook for the Clinical Trials Information System, bringing together guidance that was previously scattered across multiple platforms and documents to help sponsors navigate the trial process more efficiently.
The long-time industry executive led several drug approvals but may have a lot to learn about the intimate details of application review and the Center for Drug Evaluation and Research.
The US FDA's Psychopharmacology Advisory Committee emphasized high standards over regulatory flexibility while turning down Otsuka's brexpiprazole plus serotonin for post-traumatic stress disorder based on conflicting Phase III trials and post-hoc Phase II analyses.